Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Rebecca Tushnet
False advertising and more
Rebecca Tushnet
Rebecca Tushnet
Email subscription
ABA Blawg 100
Posts
Subscribe via RSS or LinkedIn
"Bright young [wo]man"/"Yo, who the F is this?"
Blog Archive
-
▼
2010
(312)
-
▼
November
(37)
- False advertising without harm: no new trial, no d...
- Trademark infringement claim triggered insurance c...
- FDA warning letters lack preclusive effect
- Fees available in Lanham Act cases for abuse of pr...
- Close to home: Livejournal, defamation, and person...
- Skymall as source of review questions
- Drug marketing class actions continue despite pree...
- "Steel Curtain" as mark for NFL team is slogan, tr...
- Seen today at the mall
- NYT asks for Harry Potter fan fiction
- Notre Dame 2010 Creativity and the Law Symposium p...
- Notre Dame 2010 Creativity and the Law Symposium p...
- Notre Dame 2010 Creativity and the Law Symposium p...
- Notre Dame 2010 Creativity and the Law Symposium
- Trademark infringement from sharing a specialized ...
- Standing claims another victim
- Amazon not responsible for Associate's ad
- Zynga and 230
- The line between product disparagement and defamat...
- Everybody can publicize discovery but the parties
- Head to head: literal falsity helmet claims rejected
- district court's failure to specify leads to reman...
- Sixth Circuit invalidates milk labeling rule
- Fordham: The Rise of Unbranding in Trademark Law
- Fordham: Revisiting the Doctrine of Inequitable Co...
- Fordham: Spurious Take Down Notices Under the Digi...
- eBay contract and UCL/FAL class action certified
- Enfamil class action certified
- What a headache: Kaiser wins Neurontin marketing case
- Positive tension
- Clever arguments fail to defeat preemption, standi...
- Tabs protect Target from class action
- Is it just me, or do the parties sound like Dilber...
- Multivitamins raise multiple claims
- Complete fraud justifies class action certification
- Broken contract leads to trademark and false adver...
- Formula lost: consumer claim against Enfamil fails
-
▼
November
(37)
Labels
- 1201 (18)
- 1202 (1)
- 230 (96)
- acpa (16)
- advertising (281)
- antitrust (49)
- arbitration (3)
- art law (36)
- attribution (28)
- b (1)
- blogging (23)
- california (534)
- can-spam (1)
- cfaa (12)
- cfps (46)
- class actions (276)
- cmi (19)
- comics (37)
- commercial speech (266)
- conferences (910)
- consumer protection (920)
- content moderation (2)
- contracts (99)
- copying (195)
- copyright (1635)
- counterfeiting (1)
- creative commons (12)
- cultural property (10)
- cybersquatting (1)
- damages (156)
- dastar (189)
- defamation (200)
- derivative works (2)
- design patent (56)
- dilution (256)
- disclosures (94)
- disparagement (28)
- dmca (201)
- drm (72)
- evidence (1)
- false advertising (3023)
- false association (12)
- false designation of origin (4)
- false endorsement (13)
- fan fiction (87)
- fanworks (190)
- fda (271)
- fees (35)
- first amendment (435)
- ftc (182)
- g (1)
- geographic indications (43)
- go (1)
- google (89)
- insurance (72)
- interviews (5)
- jobs (2)
- jurisdiction (5)
- libraries (18)
- misappropriation (10)
- moral rights (18)
- music (136)
- my lawsuits (16)
- my writings (111)
- net neutrality (5)
- parody (27)
- patent (222)
- patents (136)
- peer production (27)
- preemption (263)
- presentations (118)
- privacy (113)
- procedure (144)
- property (18)
- reading list (306)
- remedies (269)
- right of publicity (260)
- secondary liability (178)
- securities (8)
- standing (352)
- surveys (100)
- teaching (37)
- tortious interference (112)
- trade secrets (80)
- trademark (2015)
- traditional knowledge (11)
- unconscionability (5)
- unfairness (61)
- warranties (14)
Things I've read
Creative Commons/disclaimer
Text on this blog is licensed under a Creative Commons Attribution 2.5 License. Pictures and works quoted may be subject to other parties' copyrights.
I speak for myself. On this blog, I do not and cannot speak for Harvard Law School, the Organization for Transformative Works and/or AO3.
No comments:
Post a Comment